Leukotrienes as targets in the gut

Clinical and Experimental Allergy Reviews

Volumn 1, Issue 3, 2001, Pages 309-312

  Rask Madsen, J ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 28144457710     PISSN: 14729725     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-9725.2001.t01-1-00018.x     Document Type: Article

References (29)

1. Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. Inflammatory intermediaries in inflammatory bowel disease. Int J Color Dis 1989; 4:75-90.
2. Eberhart CE, Dubois RN. Eicosanoids and the gastrointestinal tract. Gastroenterology 1995; 109:285-301.
3. Nielsen OH, Rask-Madsen J. Mediators of inflammation in chronic inflammatory bowel disease. Scand J Gastroenterol 1996; 31 (Suppl. 216):149-59.
4. Krause W, DuBois RN. Eicosanoids and the small intestine. Prostaglandins Other Lipid Med 2000; 61:125-43.
5. Krause W, DuBois RN. Eicosanoids and the large intestine. Prostaglandins Other Lipid Med 2000; 61:145-61.
6. Henderson WR. The role of leukotrienes in inflammation. Ann Int Med 1994; 121:684-97.
7. 4 synthase activities. Proc Natl Acad Sci USA 1986; 83:857-61.
8. Murphy RC, Hammerström S, Samuelsson B. Leukotriene C, a slow reacting substance (SRS) from murine mastocytoma cells. Proc Natl Acad Sci USA 1979; 76:4274-9.
9. Maclouf J, Folco G, Patrono C. Eicosanoids and isoeicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost 1998; 79:691-705.
10. Ford-Hutchinson AW. Leukotriene antagonists and inhibitors: clinical applications. Adv Prostaglandin Thromboxane Leukot Res 1995; 23:69-74.
11. Ricote M, Li AC, Wilson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391:79-82.
12. Sharon P, Ligumsky M, Rachmilewitz D, Zor U. Role of prostaglandins in ulcerative colitis, enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978; 75:638-40.
13. 2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology 1981; 81:444-9.
14. 4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984; 86:453-60.
15. Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. In vivo profiles of eicosanoids in ulcerative colitis, Crohn's colitis, and Clostridium difficile colitis. Gastroenterology 1988; 95:11-17.
16. 2 concentrations determined by equilibrium in vivo dialysis of faeces in patients with ulcerative colitis and healthy controls. Gut 1984; 25:1271-8.
17. 4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1986; 91:837-44.
18. Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. In vivo effects of orally administered prednisolone on prostaglandin and leucotriene production in ulcerative colitis. Gut 1987; 28:1095-9.
19. Dreyling KW, Kozuschek W, Schaarschmidt K, Goebell H, Peskar BM. Role of the endogenous leukotriene system in chronic inflammatory bowel disease. Prostaglandins Clin Res 1987; 242:309-15.
20. Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J. Use of colonic eicosanoid levels as predictors of relapse in ulcerative colitis: double blind placebo controlled study on sulphasalazine maintenance treatment. Gut 1988; 29: 1316-21.
21. Rask-Madsen J, Bukhave K, Laursen LS, Lauritsen K. 5-Lipoxygenase inhibitors for the treatment of inflammatory bowel disease. Special Conference Issue. Agents Actions 1992; C37-46.
22. Laursen LS, Næsdal J, Bukhave K, Lauritsen K, Rask-Madsen J. Selective 5-lipoxygenase inhibition in ulcerative colitis. Lancet 1990; 335:683-5.
23. Kjeldsen J, Laursen LS, Hillingsø J et al. Selective blockade of leukotriene production by a single dose of the FPL 64170XX 0.5% enema in active ulcerative colitis. Pharmacol Toxicol 1995; 77:371-6.
24. Hillingsæ J, Kjeldsen J, Laursen LS et al. Blockade of leukotriene production by a single oral dose of MK-0591 in active ulcerative colitis. Clin Pharmacol Ther 1995; 57: 335-41.
25. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Enel J Med 1996; 334:1557-60.
26. Laursen LS, Lauritsen K, Bukhave K et al. Selective 5-lipoxygenase inhibition by zileuton in the treatment of relapsing ulcerative colitis: a randomized double-blind placebo-controlled multicentre trial. Eur J Gastroenterol Hepatol 1994; 6:209-15.
27. Peppercorn M, Das K, Elson C et al. Zileuton, a 5-lipoxygenase inhibitor, in the treatment of active ulcerative colitis: a double-blind, placebo controlled trial. Gastroenterology 1994; 106:A751.
28. Hawkey CJ, Dube LM, Rountree LV, Linnen PJ, Lancaster JF and the European Zileuton Study Group for Ulcerative Colitis. A trial of zileuton versus mesalamine or placebo in the maintenance of remission of ulcerative colitis. Gastroenterology 1997; 112:718-24.
29. Roberts WG, Simon TJ, Berlin RG et al. Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591. Gastroenterology 1997; 112:725-32.